- Home
- UNCY vs STRO Comparison
UNCY vs STRO Comparison
Compare UNCY & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- STRO
- Stock Information
- Founded
- UNCY 2016
- STRO 2003
- Country
- UNCY United States
- STRO United States
- Employees
- UNCY 22
- STRO N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNCY Health Care
- STRO Health Care
- Exchange
- UNCY Nasdaq
- STRO Nasdaq
- Market Cap
- UNCY 71.3M
- STRO 77.7M
- IPO Year
- UNCY 2021
- STRO 2018
- Fundamental
- Price
- UNCY $0.61
- STRO $0.90
- Analyst Decision
- UNCY Strong Buy
- STRO Hold
- Analyst Count
- UNCY 4
- STRO 7
- Target Price
- UNCY $6.38
- STRO $5.47
- AVG Volume (30 Days)
- UNCY 889.6K
- STRO 1.2M
- Earning Date
- UNCY 05-14-2025
- STRO 05-08-2025
- Dividend Yield
- UNCY N/A
- STRO N/A
- EPS Growth
- UNCY N/A
- STRO N/A
- EPS
- UNCY N/A
- STRO N/A
- Revenue
- UNCY N/A
- STRO $66,434,000.00
- Revenue This Year
- UNCY N/A
- STRO N/A
- Revenue Next Year
- UNCY $1,422.24
- STRO N/A
- P/E Ratio
- UNCY N/A
- STRO N/A
- Revenue Growth
- UNCY N/A
- STRO N/A
- 52 Week Low
- UNCY $0.20
- STRO $0.52
- 52 Week High
- UNCY $0.96
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- UNCY 49.67
- STRO 48.67
- Support Level
- UNCY $0.56
- STRO $0.86
- Resistance Level
- UNCY $0.62
- STRO $0.99
- Average True Range (ATR)
- UNCY 0.05
- STRO 0.09
- MACD
- UNCY 0.00
- STRO -0.00
- Stochastic Oscillator
- UNCY 74.83
- STRO 57.19
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.